The nation of Zimbabwe has rejected a significant US health deal worth 367 million US dollars (272 million pounds) spanning five years over Washington's request for confidential biological samples.
This move became public following a official document dated December was leaked, revealing that President Emmerson Mnangagwa deemed the arrangement was "unbalanced".
An official representative has since stated that the United States was seeking genetic material for research and commercial gain while refused to guarantee the benefits from future treatments.
"We are forced to start the challenging and unfortunate task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had donated more than $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged continued negotiations to find a deal suitable to both sides so the country's vital HIV programme can continue.
Wider Background
This rejection follows a similar case in neighbouring Kenya, where a high court halted a similar deal with the US following concerns were filed about the security of citizens' medical information.
Since returning to office recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump argued its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to enhance openness and responsibility.
Based on statements, Sixteen nations in Africa have so far signed these new health pacts, representing over $18.3bn in new funding.
Details of the Declined Deal
The funds for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data over an extended period, with no equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," he stated.
"In essence, our country would provide the raw materials for medical research without any assurance that the final treatments would be available to our citizens if a future pandemic arise."
National Interest and International Frameworks
He also pointed out that the American exit from the global health body and its push of bilateral deals were disrupting structures already established through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with potential global health emergencies.
"This system is intended to ensure that when a country provides its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to create them."
Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how future co-operation could be designed in a manner that respects the sovereignty and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but recommended that negotiations should continue considering a large portion of the country's Aids initiatives were funded by foreign aid.
"If specific concerns exist, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," the group said.
The situation highlights the ongoing debate between receiving much-needed foreign assistance and safeguarding a country's data in an increasingly data-driven world.